Human IFI35 (Interferon-Induced 35 Kda Protein) - Recombinant Protein
Beta LifeScience
SKU/CAT #: BLT-07179P

SDS-PAGE analysis of Human IFI35 (Interferon-Induced 35 Kda Protein) - Recombinant Protein, CAT# BLT-07179P, showing >95% purity under 15% SDS-PAGE (Reduced)
Human IFI35 (Interferon-Induced 35 Kda Protein) - Recombinant Protein
Beta LifeScience
SKU/CAT #: BLT-07179P
Regular price
$59500
$595.00
Sale price$44500
$445.00Save $150
/
Quantity Pricing
Pack Size | Price (USD) |
---|---|
500 µg | $1,030 (Fall Promotion) |
1 mg | $1,870 (Fall Promotion) |
For direct online orders, quantity pricing will be displayed in cart when you add 5x100ug or 10x100ug
Submit an inquiry or email inquiry@betalifesci.com for a customization request or bulk order quote.
Connect with us via the live chat in the bottom corner to receive immediate assistance.
Product Overview
Product Name | Recombinant Human Interferon Inducible 35 (IFI35) Protein |
Product Overview | This recombinant human Interferon Inducible 35 (IFI35) protein includes amino acids 2-286aa of the target gene is expressed in E.coli.The protein is supplied in liquid or lyophilized powder form and formulated in PBSprior to lyophilization. |
Target Uniprot Id | P80217 |
Recommended Name | Interferon-induced 35 kDa protein |
Gene Name | IFI35 |
Synonyms | IFP35 |
Species | Human |
Predicted Molecular Mass | 38 kDa |
Expression System | E.coli |
Expression Range | 2-286aa |
Tag | N-6His |
Purity | >95% |
Formulation | Liquid or Lyophilized powder |
Buffer | PBS |
Storage Condition | 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C. |
Reconstitution Instruction | Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%. |
Applications | Positive Control; Immunogen; SDS-PAGE; WB |
Research Area | Cell Biology |
Target Function | Acts as a signaling pathway regulator involved in innate immune system response. In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator NMI to regulate immune response; the complex formation prevents proteasome-mediated degradation of IFI35 and correlates with IFI35 dephosphorylation. In complex with NMI, inhibits virus-triggered type I interferon/IFN-beta production. In complex with NMI, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of the NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries. Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation when actively released by macrophage to the extracellular space during cell injury and pathogen invasion. Macrophage-secreted IFI35 activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of proinflammatory cytokines. |
Subcellular Location | Cytoplasm. Nucleus. Secreted. |
Protein Family | NMI family |
Tissue Specificity | Expressed in a wide range of cell types, including fibroblasts, macrophages, and epithelial cells. |